Incoming @HarvardRadOnc, @YaleMSTP; 2024 @ForbesUnder30 Healthcare; 2022 @PDSoros fellow; biotech entrepreneur; aspiring physician-scientist, and corgi owner.

New Haven, CT
Joined April 2022
Kings⌬n Lin, MD, PhD retweeted
The latest issue of JACS is live! On the cover this week: Researchers from @Yale have designed a molecule that kills brain cancer cells while giving healthy cells time to repair their DNA. @ranjitbindra @YaleCancer Learn more ➡️ go.acs.org/a6X
8
1
43
29,429
Kings⌬n Lin, MD, PhD retweeted
Landscape of ADCs by Dr. LoRusso. 11 approved ADCs among 349 ADCs that have entered the clinic (148 discontinued). Developing ADCs for solid tumor is challenging given antigens being “tumor-associated” not “specific” and heterogeneity of cancer cells among many reasons. #ASCO24
4
68
4
161
49,428
Interested in prodrugs? This review in the June issue analyses approved prodrugs and discusses trends in their development, design rationales, indications, mechanisms of API release, chemistry of promoieties and market impact bit.ly/43I3X1U rdcu.be/dIGPU
3
68
5
197
28,524
Kings⌬n Lin, MD, PhD retweeted
Exercise may be the single most potent medical intervention ever known. Its benefits in prevention outstrip any known drugs: 50% reduction in the risk of cardiovascular disease, 50% reduction in the risk of many cancers, positive effects on mental health, pulmonary health, GI health, bone health, muscle function. You name it. Exercise helps. In fact, the ability to exercise over long distances was likely key to our evolution as a species because the availability of densely caloric foods due to persistence hunting allowed our energy-avid brains to enlarge. And yet, we have had very little insight into the molecular basis of these magical effects...until now! Published in yesterday's Nature and featured on the cover was work from our consortium that represents the culmination of a couple of decades of pitching ideas to the NIH, forming a consortium, planning experiments, executing those experiments, and analyzing data at unprecedented scale, all aimed at enhancing our understanding of the molecular transducers of exercise. It was a major effort from so many in our consortium (playfully named MoTrPAC) and is the first landmark paper of many more to come. This first paper focused on the multi-tissue, multi-omics of treadmill exercise in rats. Specifically, we report the effects of eight weeks of treadmill running on the transcriptome, the epigenome, the proteome, the metabolome, the lipidome and the immunome of a broad range of tissues (in fact, 9,466 assays across 19 tissues, 25 molecular platforms, and 4 training time points). The result is the most comprehensive molecular map of exercise ever created. At Stanford, my colleague @MWheelerMD and I co-lead the bioinformatics center and it was our team's duty and privilege to ingest the data, QC the data, help analyze the data, and make the data available to the world. Various tools available at our data hub allow you to explore the data, visualize it, and download it for your own use. Have fun! And stay tuned for human data that will be coming. So many people to thank who made this possible (see the paper for details). Special shout out to the primary analysts and authors: David Amar, Nicole Gay, & Pierre Jean Baltran. Paper: nature.com/articles/s41586-0… Data hub: motrpac-data.org/
22
247
25
837
143,655
Kings⌬n Lin, MD, PhD retweeted
A huge congrats to #PDSoros Fellow @LinKingson who matched into the Harvard Radiation Oncology Program at Mass General/Brigham!
1
10
1,004
Kings⌬n Lin, MD, PhD retweeted
Gotta be honest if youre choosing a phd program based on your odds of success in VENTURE CAPITAL ive got bad news for you buddy Also go yale i guess
What graduate program’s students are most likely to achieve unicorn status if they found a VC-based company? Yale’s graduate program has the highest likelihood (1.8x the average). Stanford (1.4x), MIT (1.4x), Columbia (1.3x) and NYU (1.3x) follow. #startups #innovation #technology
3
1
39
6,587
Kings⌬n Lin, MD, PhD retweeted
The Breakthrough of the Year 2023 @ScienceMagazine GLP-1 Drugs science.org/doi/10.1126/scie…
1
117
13
376
177,312
Kings⌬n Lin, MD, PhD retweeted
Congrats to #PDSoros Fellow @LinKingson who is on the 2024 @Forbes #30under30 list! Kingson, the cofounder of Modifi Biosciences, is developing innovative, selective ways that could potentially treat deadly, drug-resistant brain cancers. forbes.com/profile/kingson-l…
1
2
22
2,137
Kings⌬n Lin, MD, PhD retweeted
As of 10 November 2022, it is estimated that 94% of Americans have had Covid at least once, much of those infections in the past year. Ranking of states w/ most vulnerability d/t lack of vaccines/ boosters medrxiv.org/content/10.1101/… @HarvardChanSPH
97
311
93
896
Kings⌬n Lin, MD, PhD retweeted
Möbius aromaticity, the "how in the hell is this aromatic" type of aromaticity. (Submitted by @/MMakaryn)
7
18
3
194
Kings⌬n Lin, MD, PhD retweeted
Coffee lovers will love this new report ;-) academic.oup.com/eurjpc/adva… @escardio @BakerResearchAu @uk_biobank ☕️☕️☕️
140
1,772
597
5,258
Kings⌬n Lin, MD, PhD retweeted
Thx so much @NIH @theNCI for featuring our recent discovery in @ScienceMagazine RE a new approach to exploit DDR defects! Vry excited 2translate this into the clinic via our latest startup, modifibio.com @YaleCancer @YaleRadOnc @Yale_Ventures nih.gov/news-events/nih-rese…
2
2
18
Kings⌬n Lin, MD, PhD retweeted
Chemists who publish negative findings should call those papers publianions instead of publications
114
1,642
329
12,362
Kings⌬n Lin, MD, PhD retweeted
Due to inflation, Gibbs energy is no longer free and now costs $8.74
21
628
65
4,404
Kings⌬n Lin, MD, PhD retweeted
A new class of glioma drugs exploits #DNA repair defects to selectively target drug-resistant tumors, researchers report in Science. The approach may represent a new paradigm for designing therapeutics to combat drug-resistant tumors. fcld.ly/2nw07ch
1
9
43
Kings⌬n Lin, MD, PhD retweeted
If you struggle with productivity, read this thread.
61
4,452
123
17,221
Kings⌬n Lin, MD, PhD retweeted
Exciting news from CureSearch Catapult Award Recipient @ranjitbindra of @YaleCancer ! The team at Modifi Bio, co-founded by Dr. Bindra, published a critical study in @Science validating the company’s novel approach to fight cancer cells w/ DNA modification globenewswire.com/news-relea…
1
2